<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>59-CENTRAL-ANTIHYPERTENSIVES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="CENTRAL ANTIHYPERTENSIVES" code="C02AC-001" /></DRUG1>
<DRUG2>
<CLASS name="BETA BLOCKING AGENTS (EXCEPT ESMOLOL)" code="C07AB-002" /></DRUG2>
<DESCRIPTION>Large increase of blood pressure in cases of sudden termination of the treatment with the central antihypertensive</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Avoid ending treatment with the central antihypertensive abruptly. Clinical monitoring.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>59-CENTRAL-ANTIHYPERTENSIVES.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="CENTRAL ANTIHYPERTENSIVES" code="C02AC-001" /></DRUG1>
<DRUG2>
<CLASS name="BETA-BLOCKING AGENTS IN HEART FAILURE" code="C07AB-003" /></DRUG2>
<DESCRIPTION>Central decrease of the sympathetic tone and vasodilator effect of the central antihypertensives, dangerous in case of heart failure treated with a beta-blocking agent and vasodilator</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
</INTERACTIONS>
